TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32175968

Group type: EXPERIMENTAL
Intervention: 5-minute informational video, placement of capnography monitors with a shortened warm-up period, laminated reminder cards, feedback during staff meetings
Number of subjects: 118

Group type: COMPARATOR
Intervention: Existing policy for capnography use
Number of subjects: 118
Study: 32175969

Group type: EXPERIMENTAL
Intervention: Detection of adverse drug events (ADEs) by clinical pharmacists through structured interviews and medication history collection.
Number of subjects: 8275
Study: 32176787

Group type: EXPERIMENTAL
Intervention: Imipenem (1 g mixed with 200 mL normal saline, infused intravenously over 3 hours at 8-hour intervals, concentration 5 mg/mL, rate of infusion 5.5 mg/min)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 25
Study: 32178232

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32178626

Group type: EXPERIMENTAL
Intervention: Endothelial function assessment using reactive hyperemia index at 4-24 hours after surgery
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Endothelial function assessment using reactive hyperemia index at postoperative day 3-5
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: L-arginine/ADMA ratio assessment at 4-24 hours after surgery
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Major adverse cardiovascular events within 30 days of surgery
Number of subjects: 83
Study: 32178676

Group type: COMPARATOR
Intervention: Polyacrylamide gel electrophoresis Lipoprint© System for lipoprotein profile analysis
Number of subjects: 19
Study: 32179133

Group type: EXPERIMENTAL
Intervention: Self-report of symptoms in patients with mild to moderate cognitive impairment
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Self-report of symptoms in patients without cognitive impairment
Number of subjects: 1047
Study: 32179633

Group type: EXPERIMENTAL
Intervention: Spartalizumab (1, 3, or 10 mg/kg Q2W; 3 or 5 mg/kg Q4W)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Spartalizumab
Number of subjects: 58
Study: 32179935

Group type: EXPERIMENTAL
Intervention: Early mobilisation during extracorporeal membrane oxygenation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32180164

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32180754

Group type: EXPERIMENTAL
Intervention: Tele-UPCAT (Tele-monitored UPper Limb Children Action Observation Training)
Number of subjects: 29
Study: 32181968

Group type: EXPERIMENTAL
Intervention: Antibacterial exposure
Number of subjects: 430
Study: 32182156

Group type: EXPERIMENTAL
Intervention: Lifirafenib (BGB-283)
Number of subjects: 0
Study: 32182364

Group type: EXPERIMENTAL
Intervention: Intralesional rituximab (4 weekly injections followed by 6 monthly injections)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional rituximab supplemented with autologous serum (for unresponsive cases)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional rituximab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intralesional rituximab and serum retreatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Follow-up after treatment
Number of subjects: 20
Study: 32182791

Group type: EXPERIMENTAL
Intervention: Everolimus at 10 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Everolimus at 10 mg/day with octreotide LAR at 30 mg/month (18 patients)
Number of subjects: 25
Study: 32182949

Group type: EXPERIMENTAL
Intervention: Curative intent radiotherapy with or without androgen deprivation therapy (ADT)
Number of subjects: 208
Study: 32183229

Group type: EXPERIMENTAL
Intervention: Zebrafish avatar model for drug efficacy studies
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chemotherapy dose conversion formula
Number of subjects: 24
Study: 32183762

Group type: EXPERIMENTAL
Intervention: Family cohesion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child-caregiver communication
Number of subjects: 0
Study: 32183803

Group type: EXPERIMENTAL
Intervention: Web-based intervention aimed at increasing preparedness for caregiving and death, including videos and informative texts, and an online peer-support discussion forum.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 0
Study: 32184035

Group type: EXPERIMENTAL
Intervention: Vaccination Maintenance Score (VMS)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Maternal quality of life score
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Number of children in the household
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Initiating breastfeeding at birth
Number of subjects: 245
Study: 32184112

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program for 12 weeks
Number of subjects: 53
Study: 32184302

Group type: EXPERIMENTAL
Intervention: Indoor environmental quality monitoring using sensors measuring air quality (carbon dioxide and coarse particles), temperature, relative humidity, light intensity, and noise levels at 1 min intervals.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Indoor environmental quality monitoring
Number of subjects: 10000
Study: 32184312

Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery
Number of subjects: 0
Study: 32184340

Group type: EXPERIMENTAL
Intervention: MRI and magnetic resonance spectroscopy (MRS) biomarkers
Number of subjects: 104

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 104
Study: 32184375

Group type: EXPERIMENTAL
Intervention: Hyperventilation defined as arterial blood gas (ABG) ≤ 35 mm Hg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Significant hyperventilation defined as ABG ≤ 30 mm Hg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Extreme hyperventilation defined as ABG ≤ 25 mm Hg
Number of subjects: 112
Study: 32184556

Group type: EXPERIMENTAL
Intervention: S2 Ahmed glaucoma valve
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: FP7 Ahmed glaucoma valve
Number of subjects: 56
Study: 32184653

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane (3 mL)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT; IV paracetamol 1g or ketoprofen 100mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Number of subjects: 272

Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 272
Study: 32184889

Group type: EXPERIMENTAL
Intervention: Proprioceptive training with Eye-Cervical Re-education Program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye-Cervical Re-education Program
Number of subjects: 0
Study: 32185074

Group type: EXPERIMENTAL
Intervention: Flap-sliding technique
Number of subjects: 15
Study: 32185462

Group type: EXPERIMENTAL
Intervention: Inactive leg (one-legged physical inactivity)
Number of subjects: 10
Study: 32185685

Group type: EXPERIMENTAL
Intervention: Vitamin K2
Number of subjects: 0
Study: 32185745

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI) 80 U twice weekly for 12 weeks
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 32186413

Group type: EXPERIMENTAL
Intervention: Herbal Medicine SH003
Number of subjects: 0
Study: 32187112

Group type: EXPERIMENTAL
Intervention: BUP-XR treatment duration >12 months
Number of subjects: 533

Group type: COMPARATOR
Intervention: BUP-XR treatment duration ≤2 months
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: BUP-XR treatment
Number of subjects: 533
Study: 32187142

Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon-assisted enteroscopy (TTS-BAE) using NaviAid AB device (anterograde approach)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon-assisted enteroscopy (TTS-BAE) using NaviAid AB device (retrograde approach)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NaviAid AB enteroscopy
Number of subjects: 34
Study: 32187457

Group type: EXPERIMENTAL
Intervention: Selumetinib (25 mg/m², oral, twice daily, continuous dosing schedule, 28-day cycles)
Number of subjects: 50
Study: 32187630

Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF) with Medigus ultrasonic surgical endostapler (MUSE)
Number of subjects: 37
Study: 32187883

Group type: EXPERIMENTAL
Intervention: Clofarabine (30 mg/m²)
Number of subjects: 18
Study: 32188417

Group type: EXPERIMENTAL
Intervention: NEPA and dexamethasone (12 mg intravenously)
Number of subjects: 149
Study: 32188473

Group type: EXPERIMENTAL
Intervention: High HGF expression
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: High CXCL12 expression
Number of subjects: 720

Group type: COMPARATOR
Intervention: Low HGF expression
Number of subjects: 720

Group type: COMPARATOR
Intervention: Low CXCL12 expression
Number of subjects: 720
Study: 32188491

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Post-partum
Number of subjects: 384
Study: 32188508

Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 0
Study: 32188593

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (4 g/day eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) as ethyl esters)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (4 g/day olive oil)
Number of subjects: 38
Study: 32188704

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered intravenously every 21 days
Number of subjects: 127
Study: 32188717

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32188971

Group type: EXPERIMENTAL
Intervention: IMMY lateral flow assay (LFA)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Galactomannan detection
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: OLM Diagnostics lateral flow device (LFD)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Combination of LFA and β-D-glucan test
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: LFA after omitting serum galactomannan
Number of subjects: 239
Study: 32189217

Group type: COMPARATOR
Intervention: Oxytocin-pretreated samples from control group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oxytocin-pretreated samples from AMA group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oxytocin-pretreated samples from MO women
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oxytocin-naïve samples from MO women
Number of subjects: 3
Study: 32189575

Group type: EXPERIMENTAL
Intervention: Minimum IVC diameter measured in M-mode
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Change in maximum IVC diameter measured in B-mode
Number of subjects: 71
Study: 32190333

Group type: EXPERIMENTAL
Intervention: HRVB + APA
Number of subjects: 70

Group type: COMPARATOR
Intervention: APA alone
Number of subjects: 70
Study: 32190413

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 1105
Study: 32190808

Group type: EXPERIMENTAL
Intervention: Dietary Guidelines for Americans (DGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study: 32190809

Group type: EXPERIMENTAL
Intervention: Whole Grain (WG) exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Refined Grain (RG) exposure
Number of subjects: 0
Study: 32190892

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D3 (25(OH)D3) concentrations
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Magnesium intake (Q3 vs. Q1)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Magnesium intake (Q4 vs. Q1)
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Combination of sufficient 25(OH)D3 (≥50 nmol/L) and high magnesium intake
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 1169
Study: 32191209

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE) with cold Belzer solution (4-10°C) and continuous oxygenation (partial pressure of oxygen of 500-600 mm Hg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Static cold storage (SCS) with Celsior solution stored on ice
Number of subjects: 220
Study: 32191330

Group type: EXPERIMENTAL
Intervention: Apatinib plus oral vinorelbine
Number of subjects: 30
Study: 32191645

Group type: EXPERIMENTAL
Intervention: Severe receptor insulin resistance (INSR)
Number of subjects: 38
Study: 32191646

Group type: EXPERIMENTAL
Intervention: Obese-NL (n = 24)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Obese-NAFLD (n = 22)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lean-NL (n = 14)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Obese-NL and Obese-NAFLD
Number of subjects: 60
Study: 32191763

Group type: EXPERIMENTAL
Intervention: Admission testing for toxigenic C. difficile colonization
Number of subjects: 62760

Group type: EXPERIMENTAL
Intervention: Continuing admission surveillance
Number of subjects: 62760
Study: 32192431

Group type: EXPERIMENTAL
Intervention: cis-atracurium 150, 100, 70, 50, 30, and 20 μg·kg
Number of subjects: 23
Study: 32192445

Group type: EXPERIMENTAL
Intervention: Novel test for assessing the effect of genetic markers on drug immunogenicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel test for analyzing drug immunogenicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel test for testing the equality of improper survival distributions of semi-continuous outcomes
Number of subjects: 0
Study: 32192573

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously over 60 min on days 1 and 15 of a 28-day cycle (part A)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nivolumab (recommended phase 2 dose) (part B)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Nivolumab (part B)
Number of subjects: 85
Study: 32192650

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Diabetic recipients (DM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-diabetic recipients (non-DM)
Number of subjects: 158
Study: 32192666

Group type: EXPERIMENTAL
Intervention: Prophylactic Amiodarone
Number of subjects: 0
Study: 32192689

Group type: EXPERIMENTAL
Intervention: Evolut R/Evolut PRO valves
Number of subjects: 411

Group type: COMPARATOR
Intervention: SAPIEN 3 valves
Number of subjects: 411
Study: 32192693

Group type: EXPERIMENTAL
Intervention: Balloon-expandable transcatheter heart valve (THV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intentional THV crimping
Number of subjects: 200
Study: 32192746

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 12 months
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 2 years
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Mortality at 2 years
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Composite major adverse cardiovascular events (MACE) at 2 years
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Bleeding at 2 years
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Risk of death and MACE by type of ACS
Number of subjects: 8757

Group type: EXPERIMENTAL
Intervention: Mortality and bleeding comparison by region
Number of subjects: 8757
Study: 32192948

Group type: EXPERIMENTAL
Intervention: Pharmacist education and intervention
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Pharmacist education
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Survey completion
Number of subjects: 321
Study: 32193248

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 193
Study: 32193258

Group type: EXPERIMENTAL
Intervention: Independent medical evaluation by an experienced GP at 6 months of unremitting sick leave
Number of subjects: 937
Study: 32193268

Group type: EXPERIMENTAL
Intervention: Clinician-based genetic test referral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted genetic testing based on clinical prediction models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted genetic testing based on biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blanket genetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: No genetic testing
Number of subjects: 0
Study: 32193378

Group type: EXPERIMENTAL
Intervention: Combined PARP (niraparib) and PD-1 (pembrolizumab) inhibition
Number of subjects: 0
Study: 32193623

Group type: EXPERIMENTAL
Intervention: Anal canal hypermetabolism in males
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Higher BMI in patients with anal canal hypermetabolism
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Predictive factors for anal canal hypermetabolism
Number of subjects: 613
Study: 32193785

Group type: EXPERIMENTAL
Intervention: web-based lifestyle intervention programs
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: logistic regression analysis
Number of subjects: 182
Study: 32193837

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Number of subjects: 3411

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Number of subjects: 3411

Group type: COMPARATOR
Intervention: Background treatment with metformin (MET) alone or MET + SU
Number of subjects: 3411
Study: 32193971

Group type: EXPERIMENTAL
Intervention: MANTA Vascular Closure Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32193990

Group type: EXPERIMENTAL
Intervention: CTAG Stent-Graft with the Active Control System
Number of subjects: 0
Study: 32194490

Group type: EXPERIMENTAL
Intervention: Psychological intervention (one session before surgery)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 400
Study: 32195186

Group type: EXPERIMENTAL
Intervention: Triplet combination of Trastuzumab, Lapatinib, and Chemotherapy
Number of subjects: 0
Study: 32195932

Group type: EXPERIMENTAL
Intervention: Drug-eluting beads transarterial chemoembolization (DEB-TACE)
Number of subjects: 37
Study: 32196557

Group type: EXPERIMENTAL
Intervention: R-CHOP14
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Model integrating MTV and MH
Number of subjects: 141
Study: 32197614

Group type: EXPERIMENTAL
Intervention: H. pylori infected subjects (n=34)
Number of subjects: 58

Group type: COMPARATOR
Intervention: H. pylori uninfected subjects (n=24)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: H. pylori eradicated subjects (n=22)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: H. pylori infected vs uninfected subjects
Number of subjects: 58
Study: 32197630

Group type: EXPERIMENTAL
Intervention: Injection of autologous MSCs (0.5-2 × 10^6 cells) after surgical scar resection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Injection of autologous MSCs
Number of subjects: 16
Study: 32198598

Group type: EXPERIMENTAL
Intervention: Leptin concentrations in overweight and obese patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: ADMA levels in overweight and obese patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adiponectin levels in overweight and obese patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Aortic pulse pressure in patients with BMI ≥ 25 kg/m²
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Leptin concentrations and LVMI/PWV relationship
Number of subjects: 62
Study: 32198674

Group type: EXPERIMENTAL
Intervention: Viscous fiber supplementation
Number of subjects: 1347
Study: 32198837

Group type: EXPERIMENTAL
Intervention: COMBO stents
Number of subjects: 3614
Study: 32198847

Group type: EXPERIMENTAL
Intervention: Quantitative changes in medial meniscus position and morphology measured via magnetic resonance imaging (MRI) before knee replacement and 2 years prior.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control knees without subsequent knee replacement (KR).
Number of subjects: 70
Study: 32199395

Group type: EXPERIMENTAL
Intervention: Functional impairment
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Other predisposing risk factors for delirium
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Predisposition for delirium
Number of subjects: 206
Study: 32199451

Group type: EXPERIMENTAL
Intervention: Pain severity measured on a 0-10 Numerical Rating Scale
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Pain distribution reported on a body Manikin
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Pain quality assessed using the McGill Pain Questionnaire
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Central aspects of pain measured using CAP-Knee
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Frailty assessed based on Fried criteria
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Disability assessed using the FRAIL questionnaire
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Fracture risk assessment
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Latent class analysis for identifying discrete subgroups and trajectories
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Exploration of recruitment bias
Number of subjects: 10000
Study: 32199466

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 62
Study: 32200083

Group type: EXPERIMENTAL
Intervention: Physicians' meetings to optimize bowel preparation
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Written and oral instructions to patients
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Admission to gastroenterology unit
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Split-dose regimens
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 1-liter polyethylene glycol-based bowel purge
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: 75% or more intake of bowel preparation
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Bedridden status
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Constipation
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 1524

Group type: COMPARATOR
Intervention: Use of anti-psychotic drugs
Number of subjects: 1524

Group type: COMPARATOR
Intervention: 7 or more days of hospitalization
Number of subjects: 1524
Study: 32200138

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily until radiological progression or death
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily
Number of subjects: 199
Study: 32200498

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) levels in participants with rapid decline in e-GFR
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Average decline in e-GFR
Number of subjects: 912
Study: 32200512

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg
Number of subjects: 206